A recent clinical study explains the possible benefits of ActiPatch Therapy for the treatment of knee osteoarthritis.

Oxford University Press, on behalf of the British Society of Rheumatology, published the study in its journal Rheumatology, according to a media release from ActiPatch maker BioElectronics Corp.

According to the release, there was a reported statistically significant reduction in pain and a significant improvement in the WOMAC physical assessments. In addition, patients in the treatment group displayed a reduced use of NSAIDs and reported an improvement in their quality of life compared to the placebo group.

BioElectronics Corp further suggests in the release that the study further demonstrates the noninvasive neuromodulation of ActiPatch Therapy as the pain pressure threshold increased.

For more information, visit BioElectronics Corp.

[Source(s): BioElectronics Corp, PR Newswire]